Abstract
Background & Aims Intrahepatic cholestasis of pregnancy (ICP) is the most common and high-risk liver disorder during the critical period of human reproduction. Despite varying prevalence across populations, a mechanistic understanding of this phenomenon is lacking. This study delves into the genetic etiology of ICP in East Asians, drawing comparisons with Europeans to comprehend ICP etiology in the context of genetic background and evolution.
Methods We conducted the hitherto largest-scale genome-wide association studies (GWAS) on total bile acid concentration (TBA) and ICP among 101,023 Chinese pregnancies. The findings were subsequently replicated in two cohorts and compared with European populations. Additionally, phenome-wide association and spatio-temporal evolution analyses were employed to understand the function and explore evolutionary pattern of sites associated with ICP.
Results We identified eight TBA and five ICP loci, including ten novel loci. Notably, we found an East-Asian-specific genetic locus at 14q24.1, contributing to a 6.41 µmol/L increase in TBA and a 15.23-fold higher risk of ICP per risk allele (95% CI: 15.10 to 15.36, P = 9.23×10-375). Phenome-wide association studies and spatial-temporal evolution analyses revealed that the 14q24.1 ICP risk locus exhibits resistance to hepatitis B infection and has become prevalent only within the last 3,000 years in East and Southeast Asia.
Conclusions Our investigations have unraveled a distinct etiology of ICP between Europeans and East Asians, and has linked ICP etiology in East Asians to a historical HBV epidemic in East and Southeast Asia within the last 3,000 years. These findings lay the groundwork for an improved biological understanding of ICP pathophysiology. Further exploration and utilization of these variations hold the potential for more precise detection, assessment, and treatment of ICP.
Lay summary Intrahepatic cholestasis of pregnancy (ICP) is a prevalent and high-risk liver disorder that occurs during pregnancy, a critical period in human reproduction. It affects approximately 1% to 6.06% pregnancies and has been associated with severe adverse outcomes such as preterm birth and stillbirth. While rare and common variants associated with ICP have been identified in the European population, the genetic basis of ICP in East Asian population remains uncharacterized. Here, we conducted the largest-scale genome-wide association studies to date for TBA and ICP among 101,023 Chinese pregnant women, including 4,703 cases and 96,320 controls from two hospitals in Shenzhen, China. We replicated our findings in two independent Chinese cohorts and compared them with ICP genetic studies in the European population. We identified eight and five genome-wide significant loci for TBA and ICP, respectively, including ten novel loci. Notably, we identified an East-Asian-specific genetic locus contributing to a 6.41 µmol/L increase in TBA per risk allele and a 15.23-fold higher risk of ICP. Further exploration through phenome-wide association studies and spatial-temporal evolution analyses revealed that the 14q24.1 ICP risk locus exhibits resistance to hepatitis B infection and has become prevalent only within the last 3,000 years in East and Southeast Asia. These findings suggest a historical HBV epidemic in East and Southeast Asia within 3,000 years may have contributed to the increased prevalence of ICP and TBA risk alleles among East Asians. Our study unravels a distinct genetic etiology of ICP between Europeans and East Asians. These findings lay the foundation for an improved understanding of ICP pathophysiology and emphasize the need for integrating population evolution into genetic medicine for personalized genomics and clinical guidance.
Highlights
(1) In the most powerful genome-wide association studies on TBA and ICP in East Asians to date, we identified eight and five genetic loci, respectively, of which, 7 and 3 were novel discoveries.
(2) One of the novel loci, the 14q24.1 locus, stands out as it contains unique causal genetic variants specific to East-Asians. These variants demonstrate large effects, contributing to an average increase of 6.41 µmol/L in TBA per risk allele and a 15.23-fold higher risk of ICP.
(3) The risk mutations associated with ICP at the 14q24.1 exhibit resistance to hepatitis B infection and has only become prevalent within the last 3000 years in East and Southeast Asia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by Shenzhen Basic Research Foundation (20220818100717002), Guangdong Basic and Applied Basic Research Foundation (2022B1515120080, 2020A1515110859), National Natural Science Foundation of China (31900487, 82203291), and the Shenzhen Health Elite Talent Training Project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee/IRB of the School of Public Health (Shenzhen) of Sun Yat-sen University gave ethical approval for this work. Ethics Committee/IRB of Longgang District Maternity and Child Healthcare Hospital of Shenzhen City gave ethical approval for this work. Ethics Committee/IRB of Shenzhen Baoan Women and Children Hospital gave ethical approval for this work. Ethics committee/IRB of the Human Genetic Resources Administration of China (HGRAC) gave approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
GWAS summary statistics for TBA and ICP phenotypes will be made publicly available in the GWAS catalog (https://www.ebi.ac.uk/gwas/) upon publication.
Abbreviations
- AADR
- Allen Ancient DNA Resource
- BRN
- Brunei
- CDX
- Chinese Dai in Xishuangbanna
- CHB
- Han Chinese in Beijing
- CHS
- Southern Han Chinese
- CI
- confidence interval
- COJO
- conditional and joint analysis
- CQ
- Chongqing (China)
- DE
- Germany
- DK
- Denmark
- ES
- Spain
- FJ
- Fujian (China)
- FSM
- Federated States of Micronesia
- GWAS
- genome-wide association study
- GX
- Guangxi (China)
- HA
- Henan (China)
- HBcAb
- hepatitis B core antibody
- HBeAb
- hepatitis B e antibody
- HBeAg
- hepatitis B e antigen
- HBsAb
- hepatitis B surface antibody
- HBsAg
- hepatitis B surface antigen
- HBV
- hepatitis B virus
- HCV
- hepatitis C virus
- HR
- hazard ratio
- ICP
- intrahepatic cholestasis of pregnancy
- ID
- Indonesia
- iHS
- integrated Haplotype Score
- IS
- Iceland
- IT
- Italy
- JPN
- Japan
- KH
- Cambodia
- LB
- Lebanon
- LD
- linkage disequilibrium
- MA
- Morocco
- MAF
- minor allele frequency
- MY
- Malaysia
- NIPT
- non-invasive prenatal testing
- OR
- odds ratio
- PCs
- principal components
- PH
- Philippines
- PNG
- Papua New Guinea
- PP.H
- posterior probability for hypothesis
- RU
- Russia
- SFS
- site-frequency spectrum
- SNP
- single nucleotide polymorphism
- TBA
- total serum bile acids
- TWN
- Taiwan (China)
- USA
- United States of America
- VAN
- Vanuatu
- VEP
- Ensembl Variant Effect Predictor
- VN
- Vietnam
- XJ
- Xinjiang (China)
- XP-EHH
- Cross Population Extended Haplotype Homozygosity.